Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA, Millipore Get US Clearance for Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck KGaA's agreement to acquire Millipore has cleared US anti-trust review, Millipore said in a filing today with the US Securities and Exchange Commission.

The firms agreed to the deal at the end of February. Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.

Millipore said in its SEC filing that the waiting period for a review by the US Department of Justice and the Federal Trade Commission had expired without a request for any additional information.

In early Wednesday afternoon trade on the New York Stock Exchange, shares of Millipore were up less than 1 percent at $106.22 per share.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.